Clinical Trial

Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2004 in patients with advanced tumors.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-07-30; most recent amendment 2026-03-04.
Status change: Not Yet Recruiting → Recruiting 2025-08-27
Trial Details
NCT Number NCT07110584
Lead Sponsor ModeX Therapeutics, An OPKO Health Company
Conditions Advanced Tumors
Enrollment 235 participants
Start Date 2025-10-01
Primary Completion 2031-06-30 (estimated)
Study Completion 2031-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-05